Official UK procurement notice
ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL
Authority: Northern Health and Social Care Trust (Central government)
What is being bought
Published requirement descriptionThe intended contract is for the supply of Enhertu (Trastuzumab Deruxtecan) 100mg powder for solution for infusion to Northern Health and Social Care Trust for the period of three years
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 13 Aug 2025, 16:46 BST
- Last source update
- 3 Sept 2025, 14:09 BST
- Authority reference
DAC134/0825PM- FTS notice number
2025/S 000-053560- Latest notice
- Contract details notice (UK7)
- Delivery area
- Official registry OCID
ocds-h6vhtk-058761Find a Tender
- Why no open competition
- Single Suppliers Technical Reasons
- Published justification
Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists.
Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract -
(a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and
(b)there are no reasonable alternatives to those goods,services or works.
The Northern Health and Social Care Trust requires the purchase of enhertu which is subject to patent protection.
These essential medicines are required from this supplier to ensure continuity of patient care.
The absence of competition is not the artificial narrowing of the parameters of the procurement.
How it was run
Official notice- Submission deadline
- —
Timeline
26 Aug 2025 → 3 Sept 2025 · 2 dates- Standstill ends26 Aug 2025, 23:59 BST
- Notice published3 Sept 2025, 14:09 BST
Notice history
4 events · 3 releases on Find a Tender · since 13 Aug 2025- Transparency notice published13 Aug 2025, 16:46 BSTUK5
- Contract award notice published14 Aug 2025, 11:52 BSTUK6
- Contract signature expected27 Aug 2025, 23:59 BSTscheduled
- Contract details notice published3 Sept 2025, 14:09 BSTUK7
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Alloga UK, NOVARTIS PHARMACEUTICALS UK LIMITEDjoint award1 Sept 2025 – 31 Aug 2028 | £700,000 | 13 Aug 2025 | Awarded |
Contracts
ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL · Alloga UK, NOVARTIS PHARMACEUTICALS UK LIMITED
- Signed
- 1 Sept 2025
- Value
- £700,000
- Period
- 1 Sept 2025 – 31 Aug 2028
- Status
- active
No agreed KPIs: Not applicable as contract value is less than £5 million
Contracting authority & participating public bodies
Bidders & participating suppliers
2 commercial parties on the notice- ALLOGA UK LIMITEDAwarded supplier
- NOVARTIS PHARMACEUTICALS UK LIMITEDAwarded supplier
Official documents & specifications (3)
Official links; attachments are not copiedNotices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Transparency notice Transparency notice on Find a Tender